Renal denervation for treatment of uncontrolled hypertension in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea)
- Authors
- Kim, B-K; Boehm, M.; Mahfoud, F.; Mancia, G.; Park, S.; Hong, M-K; Kim, H-S; Park, S-J; Park, C. G.; Seung, K. B.; Gwon, H-C; Choi, D-J; Ahn, T. H.; Kim, C. J.; Kwon, H. M.; Esler, M.; Jang, Y. S.
- Issue Date
- May-2016
- Publisher
- NATURE PUBLISHING GROUP
- Citation
- JOURNAL OF HUMAN HYPERTENSION, v.30, no.5, pp.315 - 321
- Journal Title
- JOURNAL OF HUMAN HYPERTENSION
- Volume
- 30
- Number
- 5
- Start Page
- 315
- End Page
- 321
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8319
- DOI
- 10.1038/jhh.2015.77
- ISSN
- 0950-9240
- Abstract
- Reports detailing the response of hypertensive patients to renal denervation (RDN) in Asian patients are limited. We evaluated 6- and 12-month outcomes after RDN in an Asian population and compared outcomes to a primarily Caucasian population. The Global SYMPLICITY Registry (GSR) is a prospective, all-comer, worldwide registry that evaluates the safety and effectiveness of RDN and includes the Korean registry substudy (GSR Korea) and a Caucasian subset (GSR Caucasian). Given differences in baseline characteristics among GSR Korea (n = 93) as compared with GSR Caucasian (n = 169) patients, including lower baseline office systolic blood pressure (SBP), lower body mass index and differences in medications, propensity score adjustment was performed when comparing the change in SBP between subsets. The 6- and 12-month change in SBP in GSR Korea was -19.4 +/- 17.2 and -27.2 +/- 18.1 mm Hg, respectively (P < 0.001 for both vs baseline). GSR Caucasian had a SBP change similar to GSR Korea at 6 months (-20.9 +/- 21.4 mm Hg, unadjusted P = 0.547, adjusted P = 0.998), whereas at 12 months the change was significantly less pronounced (-20.1 +/- 23.9 mm Hg, unadjusted P = 0.004, adjusted P = 0.002). There were no protocol-defined procedure-related adverse events and no chronic adverse events associated with the device in an Asian population. RDN provided a significant reduction in 6- and 12-month office SBP among Asian patients, with a favorable safety profile. The 12-month SBP reduction was larger than that observed in Caucasian patients.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8319)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.